Journavx for Pain Management: Toward Affordabil...

By Rene Pretorius

April 25, 2025

In this review I summarize the ICER 2025 evaluation report of suzetrigine (Journavx®), a new FDA-approved non-opioid oral analgesic. It targets the N...
NICE Grants Conditional Robotic Surgery Approval to Enhance Patient Care and ...
NICE Breakthrough: Record Positive Recommendations for Blood Cancer Treatment...
Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, an...
Systems Thinking in Pharmaceutical Access: Future-Proofing Value Strategy
PEPFAR Funding Pause Threatens Global HIV Progress
Evolving Cervical Cancer Treatment: Innovations and Challenges
NICE Approves Gene Therapy for Sickle Cell: A Breakthrough in Treatment and H...
Streamlining HTA – Joint Scientific Consultations in the EU
Surrogate Endpoints Guidance: New International Report Enhances HTA Practices
Cost-Effectiveness of Switching to the Nonavalent HPV Vaccine in the Netherlands
Reevaluating NICE’s Cost-Effectiveness Thresholds: The QALY Debate
Canada’s Drug Agency Launches Consultation on New Methods Guide for Hea...